Company Overview - Baxter International Inc. received FDA approval for an expanded indication for Clinolipid, allowing its use in pediatric patients, including preterm and term neonates, which is expected to enhance its Infusion Therapies and Technologies product line [1] - Clinolipid has been available for adults since 2019 and is now accessible for all age groups, indicating a significant expansion of its market reach [1] Significance of the Approval - Parenteral nutrition is crucial for treating malnutrition, with Baxter estimating that around 40% of patients receiving parenteral nutrition in the U.S. are under 18 years old [2] - Clinolipid is Baxter's proprietary mixed oil lipid emulsion, providing essential calories and fatty acids when oral or enteral nutrition is not feasible [2] - The expanded access to Clinolipid is expected to offer clinicians more options tailored to the needs of vulnerable pediatric patients [2] Industry Prospects - The global clinical nutrition market was valued at approximately $38 billion in 2023 and is projected to exceed $70.33 billion by 2032, growing at a CAGR of 6.4% [3] - Factors driving this growth include the rising incidence of chronic diseases, increased use of clinical nutritional products, and heightened concerns about pediatric malnutrition [3] - The FDA's approval for Clinolipid is anticipated to significantly benefit Baxter's business within this expanding market [3] Recent Developments - Baxter reported mid-single-digit growth in its Medical Products & Therapies segment for Q1 2024, attributed to positive demand and pricing [4] - The company also received FDA 510(k) clearance for its Novum IQ large-volume infusion pump with Dose IQ Safety Software, indicating ongoing innovation [4] Price Performance - Baxter's shares have declined by 17.3% over the past year, contrasting with a 3.5% decline in the industry and a 26.5% increase in the S&P 500 [5]

Baxter International (BAX) reported $3.59 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 1.6%. EPS of $0.65 for the same period compares to $0.59 a year ago.The reported revenue represents a surprise of +1.20% over the Zacks Consensus Estimate of $3.55 billion. With the consensus EPS estimate being $0.61, the EPS surprise was +6.56%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

FI RS T-Q UA RT ER 2024 EA RNI NGS Baxter International Inc. May 2, 2024 1 FORWA R D- LOOKING STAT EM ENT S ...

Baxter International Inc. (NYSE:BAX) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Clare Trachtman - Vice President, Investor Relations Joe Almeida - Chairman & Chief Executive Officer Joel Grade - Executive Vice President & Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Danielle Antalffy - UBS Patrick Wood - Morgan Stanley Travis Steed - Bank of America ...

Baxter International (BAX) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.56%. A quarter ago, it was expected that this drug and medical device maker would post earnings of $0.86 per share when it actually produced earnings of $0.88, delivering a surprise of 2.33%.Over the last fou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2024 RESULTS DEERFIELD, Ill., MAY 2, 2024 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024. "Baxter's results in the first quarter reflect the company's solid operational performance, fueled by the benefits being realized from our ongoing strategic transformation initiatives, including our new operating model structure, and continued strong execution across our integrated supp ...

Analysts on Wall Street project that Baxter International (BAX) will announce quarterly earnings of $0.61 per share in its forthcoming report, representing an increase of 3.4% year over year. Revenues are projected to reach $3.55 billion, declining 2.7% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a ...

Baxter International, Inc. (BAX) recently announced the expansion of its Pharmaceutical portfolio with the launch of five injectable products in the United States.The launched products are likely to provide ready-to-use formulations that promote patient needs in key therapeutic areas and benefit healthcare professionals with additional convenience.Price PerformanceIn the past six months, BAX’s shares have rallied 32.3% compared with the industry’s rise of 21.7%. The S&P 500 has gained 19.1% in the same time ...

The Zacks Medical sector is facing headwinds in the form of inflation, higher interest rates, supply-chain disruptions and high operating costs. These factors are likely to put pressure on the industry players’ margin.Amid these ongoing headwinds, the sector has gained 2.5% until Apr 9, underperforming the S&P 500 Index’s 9.4% gain.Meanwhile, amid the rising risk of a downtrend in the market, it would be a wise decision to invest in some dividend-paying companies like Cardinal Health (CAH) , Baxter Internat ...